OPHTHALMOLOGY, cilt.118, sa.5, ss.831-839, 2011 (SCI-Expanded)
Objective: To demonstrate noninferiority of a quarterly treatment regimen to a monthly regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).